Related Experiment Video
Updated: Jan 10, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
William Cross1, Iben Lyskjær2, Christopher Davies3,4
1Rare Malignancies and Cancer Evolution Group, Centre for Cancer Research, University of Reading, Reading, UK.
Abstract:
Driver mutations in IDH1 and IDH2 are initiating events in the evolution of chondrosarcoma and several other cancer types. Here, we present evidence that mutant IDH1 is recurrently lost in metastatic central chondrosarcoma. This may reflect either relaxed positive selection for the mutant IDH1 locus, or negative selection for the hypermethylation phenotype later in tumor evolution. This finding highlights the challenge for therapeutic intervention by mutant IDH1 inhibitors in chondrosarcoma.
Insights
Mutant IDH1, a driver of chondrosarcoma, is often lost in metastatic tumors. This loss complicates targeted therapies with IDH1 inhibitors for this bone cancer.
Area of Science:
- Oncology
- Cancer Genomics
- Molecular Biology
Background:
- Isocitrate dehydrogenase (IDH) mutations in IDH1 and IDH2 are key initiating events in chondrosarcoma development.
- These mutations are known drivers in various cancer types, influencing cellular metabolism and epigenetics.
Purpose of the Study:
- To investigate the role and prevalence of mutant IDH1 in the progression of metastatic central chondrosarcoma.
- To understand the evolutionary dynamics of IDH1 mutations during chondrosarcoma metastasis.
Main Methods:
- Analysis of patient tumor samples with metastatic central chondrosarcoma.
- Genomic analysis to detect the presence or loss of IDH1 mutations.
Main Results:
- Mutant IDH1 was recurrently lost in metastatic central chondrosarcoma samples.
- This loss may indicate relaxed positive selection for the IDH1 locus or negative selection against the hypermethylation phenotype.
Conclusions:
- The loss of mutant IDH1 in advanced chondrosarcoma presents a significant challenge for therapies targeting IDH1.
- Understanding these evolutionary changes is crucial for developing effective treatment strategies for chondrosarcoma.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...